Katia Beider

2.8k total citations
62 papers, 2.2k citations indexed

About

Katia Beider is a scholar working on Oncology, Immunology and Hematology. According to data from OpenAlex, Katia Beider has authored 62 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Oncology, 29 papers in Immunology and 25 papers in Hematology. Recurrent topics in Katia Beider's work include Chemokine receptors and signaling (22 papers), Immunotherapy and Immune Responses (18 papers) and Multiple Myeloma Research and Treatments (17 papers). Katia Beider is often cited by papers focused on Chemokine receptors and signaling (22 papers), Immunotherapy and Immune Responses (18 papers) and Multiple Myeloma Research and Treatments (17 papers). Katia Beider collaborates with scholars based in Israel, Germany and United States. Katia Beider's co-authors include Amnon Peled, Eithan Galun, Arnon Nagler, Hanna Wald, Michal Abraham, Ori Wald, Ido D. Weiss, Eli Pikarsky, Evelyne Zeira and Merav Darash‐Yahana and has published in prestigious journals such as Nature Communications, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Katia Beider

60 papers receiving 2.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Katia Beider Israel 26 1.2k 1.1k 667 473 176 62 2.2k
Michal Abraham Israel 26 724 0.6× 975 0.9× 431 0.6× 438 0.9× 155 0.9× 46 1.8k
Maria Antonia Frassanito Italy 30 738 0.6× 723 0.7× 1.3k 1.9× 1.0k 2.2× 184 1.0× 68 2.5k
Aurore Saudemont United Kingdom 25 1.8k 1.5× 2.0k 1.9× 695 1.0× 654 1.4× 133 0.8× 55 3.0k
Jonathan S. Maltzman United States 25 789 0.7× 1.8k 1.7× 765 1.1× 183 0.4× 184 1.0× 60 3.0k
Ines Gütgemann Germany 25 1.1k 0.9× 1.2k 1.1× 1.3k 1.9× 181 0.4× 191 1.1× 60 3.0k
Lynne Collins United States 16 1.1k 0.9× 1.4k 1.3× 741 1.1× 391 0.8× 100 0.6× 21 2.4k
Jiang Zhu China 27 624 0.5× 1.4k 1.3× 1.0k 1.5× 1.0k 2.2× 109 0.6× 60 2.8k
Mizuko Mamura Japan 28 1.5k 1.2× 1.8k 1.6× 1.6k 2.4× 181 0.4× 154 0.9× 52 3.9k
Shiang Huang China 29 910 0.8× 809 0.7× 1.3k 2.0× 402 0.8× 81 0.5× 86 2.6k

Countries citing papers authored by Katia Beider

Since Specialization
Citations

This map shows the geographic impact of Katia Beider's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katia Beider with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katia Beider more than expected).

Fields of papers citing papers by Katia Beider

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katia Beider. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katia Beider. The network helps show where Katia Beider may publish in the future.

Co-authorship network of co-authors of Katia Beider

This figure shows the co-authorship network connecting the top 25 collaborators of Katia Beider. A scholar is included among the top collaborators of Katia Beider based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katia Beider. Katia Beider is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ostrovsky, Olga, Katia Beider, Hila Magen, et al.. (2023). Effect of HPSE and HPSE2 SNPs on the Risk of Developing Primary Paraskeletal Multiple Myeloma. Cells. 12(6). 913–913. 2 indexed citations
2.
Allen, Daniel, Lucien E. Weiss, Michael A. Rosenberg, et al.. (2022). High-Throughput Imaging of CRISPR- and Recombinant Adeno-Associated Virus–Induced DNA Damage Response in Human Hematopoietic Stem and Progenitor Cells. The CRISPR Journal. 5(1). 80–94. 16 indexed citations
3.
Allen, Daniel, Atar Lev, Yu Nee Lee, et al.. (2022). Multiplex HDR for disease and correction modeling of SCID by CRISPR genome editing in human HSPCs. Molecular Therapy — Nucleic Acids. 31. 105–121. 23 indexed citations
4.
Danylesko, Ivetta, Roni Shouval, Noga Shem‐Tov, et al.. (2020). Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphoma. Bone Marrow Transplantation. 56(5). 1134–1143. 23 indexed citations
5.
6.
7.
Beider, Katia, Hila Magen, Jonathan Canaani, et al.. (2019). The mTOR inhibitor everolimus overcomes CXCR4-mediated resistance to histone deacetylase inhibitor panobinostat through inhibition of p21 and mitotic regulators. Biochemical Pharmacology. 168. 412–428. 14 indexed citations
8.
Peled, Amnon, Shiri Klein, Katia Beider, Jan A. Burger, & Michal Abraham. (2018). Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies. Cytokine. 109. 11–16. 69 indexed citations
9.
Abraham, Michal, Yaron Pereg, Baruch Bulvik, et al.. (2017). Single Dose of the CXCR4 Antagonist BL-8040 Induces Rapid Mobilization for the Collection of Human CD34+ Cells in Healthy Volunteers. Clinical Cancer Research. 23(22). 6790–6801. 41 indexed citations
10.
Klein, Shiri, Michal Abraham, Baruch Bulvik, et al.. (2017). CXCR4 Promotes Neuroblastoma Growth and Therapeutic Resistance through miR-15a/16-1–Mediated ERK and BCL2/Cyclin D1 Pathways. Cancer Research. 78(6). 1471–1483. 48 indexed citations
11.
Abraham, Michal, Shiri Klein, Baruch Bulvik, et al.. (2017). The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression. Leukemia. 31(11). 2336–2346. 86 indexed citations
12.
Beider, Katia, Avichai Shimoni, Merav Leiba, et al.. (2016). The Sphingosine-1-Phosphate Modulator FTY720 Targets Multiple Myeloma via the CXCR4/CXCL12 Pathway. Clinical Cancer Research. 23(7). 1733–1747. 33 indexed citations
13.
Beider, Katia, Merav Darash‐Yahana, Maya Koren‐Michowitz, et al.. (2014). Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML In Vitro and In Vivo. Molecular Cancer Therapeutics. 13(5). 1155–1169. 51 indexed citations
14.
Peled, Amnon, Michal Abraham, Irit Avivi, et al.. (2013). The High-Affinity CXCR4 Antagonist BKT140 Is Safe and Induces a Robust Mobilization of Human CD34+ Cells in Patients with Multiple Myeloma. Clinical Cancer Research. 20(2). 469–479. 70 indexed citations
15.
Beider, Katia, Elena Ribakovsky, Michal Abraham, et al.. (2013). Targeting the CD20 and CXCR4 Pathways in Non-Hodgkin Lymphoma with Rituximab and High-Affinity CXCR4 Antagonist BKT140. Clinical Cancer Research. 19(13). 3495–3507. 48 indexed citations
16.
Barashi, Neta, Ido D. Weiss, Ori Wald, et al.. (2013). Inflammation-Induced Hepatocellular Carcinoma Is Dependent on Ccr5 in Mice. Hepatology. 58(3). 1021–1030. 59 indexed citations
17.
Weiss, Ido D., Michal Abraham, Katia Beider, et al.. (2012). In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non–small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery. 144(5). 1167–1175.e1. 56 indexed citations
18.
Weiss, Ido D., Ori Wald, Hanna Wald, et al.. (2010). IFN-γ Treatment at Early Stages of Influenza Virus Infection Protects Mice from Death in a NK Cell-Dependent Manner. Journal of Interferon & Cytokine Research. 30(6). 439–449. 80 indexed citations
19.
Wald, Ori, Ido D. Weiss, Hanna Wald, et al.. (2006). IFN-γ Acts on T Cells to Induce NK Cell Mobilization and Accumulation in Target Organs. The Journal of Immunology. 176(8). 4716–4729. 77 indexed citations
20.
Grabovsky, Valentin, Ori Wald, Ido D. Weiss, et al.. (2004). Differential usage of VLA‐4 and CXCR4 by CD3+CD56+ NKT cells and CD56+CD16+ NK cells regulates their interaction with endothelial cells. European Journal of Immunology. 34(5). 1333–1341. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michal Abraham Breakdown of academic impact, for papers by Maria Antonia Frassanito Breakdown of academic impact, for papers by Aurore Saudemont Breakdown of academic impact, for papers by Jonathan S. Maltzman Breakdown of academic impact, for papers by Ines Gütgemann Breakdown of academic impact, for papers by Lynne Collins Breakdown of academic impact, for papers by Jiang Zhu Breakdown of academic impact, for papers by Mizuko Mamura Breakdown of academic impact, for papers by Shiang Huang
Rankless by CCL
2026